Statins in stroke: prevention, protection and recovery (Q36390817)

13 August 2017

1 reference

title

Statins in stroke: prevention, protection and recovery (English)

1 reference

13 August 2017

Jeffrey A Switzer

1

1 reference

PubMed ID

16466299

13 August 2017

David C Hess

series ordinal

2

1 reference

13 August 2017

1 February 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

2

1 reference

13 August 2017

195-202

1 reference

Tissue plasminogen activator for acute ischemic stroke

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the Stroke Council of the American Heart Association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Smoking cessation and decreased risk of stroke in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Cigarette smoking as a risk factor for stroke. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Is cholesterol a risk factor for stroke?: Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Stroke and cholesterol: weakness of risk versus strength of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Is cholesterol a risk factor for stroke?: No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Cholesterol as a risk factor for stroke: the fugitive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Cholesterol is associated with stroke, but is not a risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Cholesterol and the risk of ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Statins for stroke prevention: disappointment and hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Targeting eNOS for stroke protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Rho GTPases and signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Beyond lipid lowering: the role of statins in vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Statins and stroke: evidence for cholesterol-independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Withdrawal of statin treatment abrogates stroke protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Favorable outcome of ischemic stroke in patients pretreated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

HMG-CoA reductase inhibitors improve acute ischemic stroke outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Expanding indications for statins in cerebral ischemia: a quantitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

Pravastatin Therapy and the Risk of Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.2.195

21 January 2018

Identifiers

DOI

10.1586/14737175.6.2.195

1 reference

13 August 2017

1 reference

PubMed ID

16466299